Abstract:Inactivation of p53 is present in almost every tumor, and hence, p53-reactivation strategies are an important aspect of cancer therapy. Common mechanisms for p53 loss in cancer include expression of p53-negative regulators such as MDM2, which mediate the degradation of wildtype p53 (p53 alpha), and inactivating mutations in the TP53 gene. Currently, approaches to overcome p53 deficiency in these cancers are limited. Here, using non-small cell lung cancer and glioblastoma multiforme cell line models, we show that two alternatively spliced, functional truncated isoforms of p53 (p53 beta and p53 gamma , comprising exons 1 to 9 beta or 9 gamma , respectively) and that lack the C-terminal MDM2-binding domain have markedly reduced susceptibility to MDM2-mediated degradation but are highly susceptible to nonsense-mediated decay (NMD), a regulator of aberrant mRNA stability. In cancer cells harboring MDM2 overexpression or TP53 mutations downstream of exon 9, NMD inhibition markedly upregulates p53 beta and p53 gamma and restores activation of the p53 pathway. Consistent with p53 pathway activation, NMD inhibition induces tumor suppressive activities such as apoptosis, reduced cell viability, and enhanced tumor radiosensitivity, in a relatively p53-dependent manner. In addition, NMD inhibition also inhibits tumor growth in a MDM2-overexpressing xenograft tumor model. These results identify NMD inhibition as a novel therapeutic strategy for restoration of p53 function in p53-deficient tumors bearing MDM2 over expression or p53 mutations downstream of exon 9, subgroups that comprise approximately 6% of all cancers.

p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi

A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Regulated secretion of mutant p53 negatively affects T lymphocytes in the tumor microenvironment

P53 Mutation and Deletion Contribute to Tumor Immune Evasion

p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression

Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins

p53 signaling in cancer progression and therapy

Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90 Secretion

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer

Antitumorigenic potential of Lactobacillus-derived extracellular vesicles: p53 succinylation and glycolytic reprogramming in intestinal epithelial cells via SIRT5 modulation

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade

Snail1-dependent P53 Repression Regulates Expansion and Activity of Tumour-Initiating Cells in Breast Cancer

Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response

Differential Regulation Of The Reg Gamma-Proteasome Pathway By P53/Tgf-Beta Signalling And Mutant P53 In Cancer Cells

TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications